SCHEDULE: Acuta Capital Discloses 9% Stake in Whitehawk Therapeutics

Acuta Capital Partners and Anupam Dalal have reported a 9% beneficial ownership stake in Whitehawk Therapeutics following a private placement.

Summary

• Acuta Capital Partners, LLC, Acuta Capital Fund, LP, and Anupam Dalal filed a Schedule 13D reporting a combined beneficial ownership of 4,843,775 shares of Whitehawk Therapeutics, Inc. common stock.
• This represents approximately 9.0% of the company's 53,783,329 outstanding shares.
• The acquisition was driven by a private placement (PIPE financing) that closed on May 14, 2026, at a purchase price of $3.92 per share.
• The reporting persons state the investment is for portfolio purposes, citing their belief that the stock was undervalued at the time of purchase.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while the capital raise provides necessary liquidity, the resulting dilution and potential for future activist involvement create a balanced outlook for shareholders.

Positives

• The investment reflects confidence from an institutional investor in the company's long-term value.
• The company successfully raised capital through a private placement, strengthening its balance sheet.
• Anupam Dalal, a key figure at Acuta, serves on the Issuer's board of directors, ensuring alignment between major shareholders and management.

Negatives

• The issuance of new shares in the private placement results in dilution for existing shareholders.
• The reporting persons reserve the right to sell their holdings or engage in hedging transactions, which could create future downward pressure on the stock price.

Risks

• The company is subject to market volatility and general economic conditions that may affect the trading price of its common stock.
• The reporting persons may influence corporate strategy, including potential mergers, consolidations, or changes in control, which may not align with all shareholder interests.
• The company has obligations under a Registration Rights Agreement to file a resale registration statement, which could lead to increased selling pressure once effective.

Future Outlook

The reporting persons intend to monitor the Issuer's operations, financial position, and market conditions. They may increase or decrease their holdings, or recommend strategic actions to the board, including potential mergers, acquisitions, or changes in capitalization.

Management Comments

• The reporting persons believe the Common Stock was undervalued and represented an attractive investment opportunity.
• The reporting persons have no present plan or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D, but may recommend actions to management.

Industry Context

StockSavvy.ai notes that private placements (PIPEs) in the biotechnology sector are common vehicles for raising capital to fund clinical trials and operational runway. The involvement of an activist-leaning investment firm like Acuta Capital often signals a desire for closer oversight of the company's strategic direction.

Comparison to Industry Standards

• The use of PIPE financing is a standard industry practice for small-cap biotech firms to secure liquidity without the immediate regulatory burden of a public offering.
• The 9% ownership threshold is consistent with significant minority positions held by institutional investors in the life sciences sector.

Corporate Governance

Related Party Transactions

• Anupam Dalal, a director of the Issuer, is the manager and control person of Acuta Capital Partners, LLC.

Stakeholder Impact

• Existing shareholders face dilution due to the issuance of 1,275,510 shares in the private placement.
• The company gains capital to support its business development and operational goals.

Next Steps

• The Issuer is required to file a resale registration statement with the SEC within 30 days of the May 14, 2026, closing.
• The Issuer will use commercially reasonable efforts to have the registration statement declared effective within 60 to 90 days.

Key Dates

Recommendation

The stock is currently in a transition phase following a capital raise. Investors should hold until the company demonstrates effective use of the new capital and the market absorbs the potential supply from the upcoming resale registration.

Keywords

Whitehawk Therapeutics, Acuta Capital, Schedule 13D, PIPE Financing, Biotech Investment, Equity Ownership